Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21961209 | 1.00 | TYK2 (0.78) | TYK2 | |
| SCHEMBL21947829 | 1.00 | TYK2 (0.78) | TYK2 | |
| SCHEMBL21962891 | 0.91 | TYK2 (0.83) | TYK2 | |
| SCHEMBL21947170 | 0.90 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21964715 | 0.89 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21961208 | 0.89 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21960522 | 0.89 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21960737 | 0.89 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21946999 | 0.89 | TYK2 (0.80) | TYK2 | |
| SCHEMBL21947772 | 0.89 | TYK2 (0.80) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | NIMBUS LAKSHMI, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TYK2, JAK1, MATK | TYK2 1/4885 |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | TYK2, JAK1, JAK2 | TYK2 1/4885 |
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TYK2, JAK1, JAK2 | TYK2 1/4885 |
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.